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The temporal pattern of the occurrence of second primary malig-
nant neoplasms after a cancer in childhood is of major clinical
importance in determining the risk/benefit balance of different
treatments. It plays a critical role in the estimation of the lifetime
excess risk experienced by childhood cancer survivors.
Secondary leukaemias occurring after chemotherapy alone
(Curtis et al, 1992; Hawkins et al, 1992) and their radiotherapy-
induced counterparts, as well as those occurring after a combina-
tion of radiotherapy and chemotherapy (Tucher et al, 1987;
Andrieu et al, 1990; Henry Amar and Dietrich, 1993; Olsen et al,
1993) appear to exhibit a wave-like temporal pattern, with most of
the excess occurring within 10 years of the first cancer. Their
temporal pattern of onset is not substantially different from that of
leukaemias following irradiation for a non-malignant disease or
for a non-medical reason (UNSCEAR, 1994).
A recent analysis of data on the Japanese atomic bomb
survivors showed a significant decrease in the relative risk of solid
cancer with follow-up after irradiation (UNSCEAR, 1994;
Thompson et al, 1994). Although such a decline was not identified
in previous analyses of this cohort (Pierce et al, 1991), it had been
demonstrated by Little et al (1991, 1997) who pooled three cohorts
including the atomic bomb survivors. Such a decrease has also
been confirmed for breast cancer incidence among A-bomb
survivors who were less than 20 years of age at the time of expo-
sure (Tokunaga et al, 1994).
In contrast, the pattern of the variation of the risk of solid
second malignancy after a first cancer in childhood is not well
known. Indeed, the variation, or the absence of variation, of the
risk observed in the major cohorts could be due to a real variation
in the risk, or to an effect of the first cancer treatment of patients
which varied with time (Tucker et al, 1984; Hawkins et al, 1987;
Olsen et al, 1993). Patients with a longer follow-up were neces-
sarily treated a longer time ago, and often according to protocols
no longer used. Satisfactory control for such sources of variation
in the risk of second malignant neoplasm (SMN) requires not only
detailed information about amount and type of each chemo-
therapeutic drug, but also radiodosimetry to estimate the radiation
dose delivered to each potential anatomical site of second cancer,
for each child in the cohort.
We present here the results of a cohort study of 4400 3-year
survivors of a childhood cancer monitored in order to evaluate the
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long-term risk of SMN after a first cancer in childhood. A prelim-
inary ‘note’ concerning some of these children, those treated by
radiotherapy alone, has been published (de Vathaire et al, 1995). In
the present report, we compare the variation of the risk with time
since first cancer, according to the type of treatment, with
emphasis on the comparison between radiotherapy alone and
radiotherapy plus chemotherapy.
PATIENTS AND METHODS
Patients
A cohort of 4400 children treated in eight centres in France and
the UK was established comprising patients who were alive
3 years after the first cancer, diagnosed before the age of 17
years and before 1986. All patients fulfilling these criteria in
Table 1 General characteristics of the cohort of 4400 3-year survivors of a first cancer in childhood
First cancer Patients Mean year of
first cancer Mean age at Mean Type of the first cancer treatment
treatment Females first cancer follow-up
(%) (years) (years) Rt, no Ct (%) Ct, no Rt (%) Rt + Ct (%)
Ewing’s sarcoma 148 1976 36 9 12 9 5 86
Bone sarcoma 143 1977 42 12 12 23 37 29
Soft tissue sarcoma 588 1974 45 6 15 17 21 49
Neuroblastoma 566 1975 50 2 15 16 31 40
Wilm’s tumour 816 1973 47 3 16 11 24 62
Central nervous system 722 1972 51 7 16 59 1 25
Bilateral retinoblastoma 82 1978 49 1 12 29 1 67
Unilateral retinoblastoma 59 1977 45 3 13 25 18 39
Hodgkin’s disease 374 1975 35 10 13 23 8 68
Non-Hodgkin’s lymphoma 456 1977 28 8 12 9 39 51
Others 446 1975 51 7 15 28 25 28
Total 4400 1974 45 6 15 24 20 47
Rt, radiotherapy; Ct, chemotherapy.
Table 2 Treatment characteristics for 3109 children who received radiotherapy, and mean radiation dose to some selected organs for 2831 patients for whom
dose estimation was possible
First cancer Radiotherapy (n = 3109) External radiotherapy with reconstruction of the dosimetry (n = 2831)
Total Brachytherapy External Mean no.
(n)( n) radiotherapy Typea of fractions Mean radiation dose in Gy
DosimetryDosimetry rx low Cobalt rx high e-(n) Cible Brain Thyroid BreastsDigestive
not possible energy (n) energy volume tract
possible (n)( n)( n) (tumour)
(n)
Ewing’s sarcoma 141 1 26 114 4 89 30 17 26 74 1.8 2.8 5.6 7.1
Bone sarcoma 74 0 10 64 0 53 12 3 23 67 0.3 2.7 8.0 5.4
Soft tissue sarcoma 390 51 41 298 40 207 38 55 20 62 5.4 5.7 3.1 6.2
Neuroblastoma 317 0 15 302 66 168 29 54 16 34 2.3 3.5 5.5 8.4
Wilm’s tumour 599 1 19 579 135 373 105 7 19 35 0.6 2.7 7.2 11.9
Central nervous system 604 9 19 576 86 383 145 89 29 74 25.3 6.2 2.0 3.9
Bilateral retinoblastoma 79 8 2 69 3 18 23 34 21 52 10.1 0.9 0.7 0.5
Unilateral retinoblastoma 36 2 1 33 5 12 1 16 24 49 8.6 2.2 1.6 1.4
Hodgkin’s disease 342 1 19 322 24 147 179 31 24 61 3.3 23.4 11.1 13.4
Non-Hodgkin’s lymphoma 274 2 8 264 25 204 46 19 17 42 14.6 7.0 3.1 5.1
Others 253 21 22 210 29 153 46 24 23 66 5.1 9.4 4.9 12.2
Total 3109 96 182 2831 417 1807 654 349 22 55 8.6 7.0 5.1 8.1
aPatients may have been treated with more than one type of machine.1886 F de Vathaire et al
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each participating centre were included. In British centres, patients
with retinoblastoma were not included because they were the
subject of a specific study (Hawkins et al, 1996). In both French
and British centres, patients with leukaemia were not included
(as either a first or a second cancer).
Clinical and histopathological characteristics of the first and
second cancers, type of treatment, detailed information on
chemotherapy, follow-up data and medical information about
second cancers, were recorded from hospital clinical records by
physicians or by a specialized data manager (British centres).
Radiotherapy data were obtained from hospital technical radio-
therapy records by physicians or hospital physicists. The mean
year of first cancer treatment was 1974 (Table 1). The end-point of
the cohort analysis was 1 January 1992 for patients treated in
French centres and 1 January 1991 for those treated in British
centres.
In 1995, a primary publication concerning only patients treated
with radiotherapy alone (de Vathaire et al, 1995), dealt with 1055
patients and 26 solid SMN. Since this publication
a. Eight patients who had been defined by mistake as in the
‘radiotherapy alone’ or in the ‘radiotherapy + chemotherapy’
group, have been reclassified in their true group of treatment.
b. We decided to keep only the 3-year survivors in the analysis,
rather than 2-year survivors as in the previous publication,
because the British patients were 3-year survivors
c. About a year of average follow-up was added.
Radiation dosimetry
Of the 4400 patients, 3109 received radiotherapy (Rt). Dose esti-
mation was not performed for the 96 patients who received
brachytherapy. These 96 patients were excluded from the
dose–response study. Among the 3013 other patients, dose estima-
tion was not possible for 182 patients due to insufficient informa-
tion, radiotherapy outside of a study treatment centre or irradiation
of arms for which the positioning was unclear (Table 2). For each
of the remaining 2831 patients who had received radiotherapy,
absorbed radiation doses were estimated at 151 points of the body.
The individual dose calculation required for this study was
performed with a software package, Dos_EG, which was devel-
oped for retrospective studies at the Institut Gustave Roussy (IGR)
(Grimaud et al, 1994; Diallo et al, 1996; Shamsaldim et al, 1998).
This software is based on auxological methods (Sempé, 1979) and
is based on a previous model developed at IGR (François et al,
1988a, 1988b), in that:
i. the individual phantom is articulated, thus allowing for trunk
inclination and back extension of the head as for mantle treat-
ments
ii. the parameters used to adapt the generated phantom to the
patient are increased to 12, allowing for better adaptation
iii.it localizes 151 anatomical sites using a Cartesian co-ordinate
system instead of 64 as in the previous one.
For more than 50% of patients appropriate anatomical data
(height, anterior–posterior thickness and left–right width) were
available. For the others the standard anatomical dimensions of the
French population corresponding to the same sex and age were
used. For all patients the radiotherapy data mentioned above were
available. For most of the radiotherapy machines used for this
population, appropriate measurements were introduced to the soft-
ware Dos_EG and used in dose calculations. For the others (ten of
the 38 machines) the characteristics of similar machines at other
centres were used.
Table 2 describes the characteristics of the treatment of the 3013
patients who received only external radiotherapy and the mean
radiation dose delivered to some selected organs.
Chemotherapy measurement
Chemotherapy (Ct) doses could not be found for 104 of the 2949
patients who had received chemotherapy (Table 3). Drugs were
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Table 3 Treatment characteristics for 2949 children who received chemotherapy, and mean number of moles m–2 by type of drug for 2845 patients for whom
chemotherapy reconstruction was possible
First cancer Chemotherapy All drugs (n = 2845) Electrophiles Topoisomerase II Inhibitors of Spindle inhibitors
agents (n = 2050) inhibitors  (n = 2132) nucleotide (n = 2438)
synthesis (n = 605)
Total Reconstruction Mean Mean % Mean % Mean number % Mean number % Mean number
(n) not possible number of number of number of of moles m–2 of moles m–2 of moles m–2
(n) agents moles m–2 moles m–2
Ewing’s sarcoma 134 2 4.0 71 91 76 83 1.61 5 9.7 83 0.035
Bone sarcoma 94 5 3.1 113 56 29 59 0.55 57 169.9 30 0.026
Soft tissue sarcoma 414 8 2.7 30 64 46 69 0.49 4 9.7 64 0.032
Neuroblastoma 403 18 2.1 23 67 32 35 1.31 2 72.6 65 0.022
Wilm’s tumour 701 17 1.8 4 9 42 81 0.18 1 1.1 64 0.031
Central nervous system 184 9 0.6 4 20 14 3 1.00 5 30.3 22 0.027
Bilateral retinoblastoma 56 11 1.7 17 60 28 36 0.21 2 0.2 54 0.012
Unilateral retinoblastoma 32 3 1.4 16 52 31 30 0.07 2 0.3 46 0.014
Hodgkin’s disease 286 15 3.0 26 70 36 21 1.88 2 5.6 72 0.097
Non-Hodgkin’s lymphoma 407 5 5.8 156 84 41 80 0.82 79 149.1 86 0.030
Others 238 11 1.9 12 40 24 44 0.50 17 12.0 37 0.033
Total 2949 104 2.4 35 48 38 49 0.64 14 115.9 57 0.036Second cancers after a first cancer in childhood 1887
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grouped into five classes according to their known mechanism of
action in the cell: electrophil agents, spindle inhibitors, inhibitors
of nucleotide synthesis, topoisomerase II inhibitors and other
drugs. In order to quantify the total amount of drug administered in
each class, we chose to convert the dose of each cytotoxic agent to
moles per square meter, rather than to milligrams per square meter.
However, we also analysed the data assuming equivalent carcino-
genic effect per mg m2 to ascertain whether this affected our
conclusions.
Statistical analysis
In order to estimate the expected number of cancers, by sex, 5-year
calendar period and 5 years of attained age, we used data from the
Danish Cancer Registry (Parkin et al, 1992). This registry was
chosen because French registries did not cover the study period,
and because differences in cancer incidence in Europe are very
small for those under 45 years of age (Parkin et al, 1993), the
maximal age attained by only 1% of our patients during the
follow-up period. Another reason is that Danish data have been
used in many other European studies. The expected number of
cancers was obtained for each sex, 5-year age group and 5-year
calendar period, by multiplying the incidence rate observed in
Denmark by the number of person-years (PY) at risk.
With the exception of total body irradiation, radiotherapy
delivers extremely heterogeneous irradiation with different parts
of the body receiving very different doses. The concept of an
average whole body dose was therefore considered unsatisfactory.
The temporal pattern of occurrence of brain, breast and thyroid
cancer was hence analysed adjusting for, respectively, dose to
brain (nine anatomical points), breast (two anatomical points) and
thyroid (three anatomical points). This type of analysis was not
possible for bone, soft tissue sarcomas and skin cancers, because
the anatomical sites vary are widely distributed over the body.
The ratio between the observed number and the expected
number of SMN was the relative risk (RR) and was modelled
assuming that the number of SMN followed a Poisson distribution
(Breslow and Day, 1987). Similarly, the excess absolute risk
(EAR) was defined as the difference between the observed and the
expected number of SMN, and expressed in relation to the number
of PY at risk. Statistical tests were performed by comparing the
deviance of nested models (Breslow and Day, 1987).
The analysis was done stratifying for the first cancer type,
except when the aim of the analysis was to check a predisposition
for a given type of second cancer to develop after a given first
cancer, in which case the analysis was performed by introducing
an indicator variable for first cancer type in the log-linear term.
AMFIT Software was used for these analyses (Preston et al, 1993).
Ninety-five percent confidence intervals (95% CI) for parameters
were estimated using maximum likelihood (Moolgavkar and
Venzon, 1987).
A debate exists concerning the best way to take into account the
variation in the risk of cancer with time: time since first cancer or
attained age (Kellerer and Barclay, 1992). We were not able to
contribute to this debate. Indeed, in our cohort, all patients were
younger than 15 years old at the time of irradiation, and thus the
time since first cancer and the attained age were too closely
related. Hence we reported variations in EAR in of RR according
to these two time scales.
RESULTS
Before the end of the study, 532 (12%) of the 4400 children were
lost to follow-up and 578 (13%) had died. The mean follow-up
was 15 years (range 3–48 years) and 1062 children (24%) were
followed up 20 years or more. A total of 113 patients (2.6%)
developed a solid SMN (all SMN but leukaemias), after excluding
non-melanoma skin cancer. The cumulative incidence of solid
Table 4 Number of patients, observed and expected number of SMN, 25 years cumulative incidencea, excess absolute risk (EAR) and
relative risk (RR) of solid SMN, by type of first cancer
First cancer Solid SMN
O E 25-year EAR/104 PY RR+ (95% Cl)
incidence (%) (95% Cl)
and 95% Cl
Ewing’s sarcoma 11 0.37 10 (3–16) 75 (38–131) 30 (15–51)
Bone sarcoma 1 0.46 2 (0–5) 5 (< 0–29) 2 (0–10)
Soft tissue sarcoma 22 1.63 7 (4–11) 29 (18–44) 13 (9–20)
Neuroblastoma 10 1.07 3 (1–6) 11 (4–22) 9 (5–16)
Wilm’s tumour 11 2.06 3 (1–6) 8 (3–15) 5 (3–9)
Central nervous system 15 2.80 3 (1–5) 14 (7–23) 5 (3–9)
Bilateral retinoblastoma 7 0.09 13 (2–24) 93 (39–181) 80 (35–155)
Unilateral retinoblastoma 0 0.08 0 – –
Hodgkin’s disease 13 1.08 7 (2–12) 29 (14–49) 12 (7–20)
Non-Hodgkin’s lymphoma 12 1.00 10 (3–17) 24 (12–43) 12 (6–20)
Others 11 1.70 4 (1–6) 18 (8–32) 6 (3–11)
Total 113 12.35 4.9 (3.1–5.9) 19 (15–23) 9.2 (7.6–11)
aFirst 3 years of follow-up were not taken into account. O: observed number of SMN, E: Expected number of SMN.1888 F de Vathaire et al
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SMN was 4.9%, (95% CI; 3.7–5.8%) 25 years after treatment of
first cancer and 7.7% (95% CI; 5.0–8.2%) 30 years after (Table 4).
During the follow-up period, 12.9 solid SMN were expected in
our cohort, leading to a RR of 9.2 (95% CI; 7.6–11), similar among
males (RR = 10) and females (RR = 8). Each year, on average, the
excess absolute risk of cancer among these survivors was 188
cases per 105 PY (95% CI; 152–230) (Table 4). Both the RR and
EAR of SMN were significantly higher among patients treated
for bilateral retinoblastoma (P < 0.0001) and Ewing’s sarcoma
(P < 0.001) as the first cancer than for other cancers (Table 4).
The RR of SMN decreased with the time since first cancer, from
16 (95% CI; 12–21) between 3 and 9 years after the first cancer
to 11 (95% CI; 8–15) between 10 and 19 years, 6 (95% CI; 3–8)
between 20 and 29 years, and 1.7 (95% CI; 0.5–4) after 30 years or
more (Table 5). This gradual decrease was significant (P < 0.001)
after adjustment for sex, age at diagnosis, first cancer type, radio-
therapy (yes/no) and the total number of moles of all electrophil
agents. The EAR of solid SMN increased non-significantly
(P = 0.1) with time after the first cancer (Table 5): 157 cases per
105 PY (95% CI; 112–211) 3–9 years after the first cancer, 214
(95% CI; 151–290) 10–19 years after, 269 (95% CI; 147–433)
20–29 years after, and 161 cases per 105 PY (95% CI; 0–560)
30 years after or more. We were not able to show a significant
interaction (P = 0.2) between the type of first cancer and the
Table 5 Relative risk (RR) and excess absolute risk (EAR) per 10–4 person-years of solid SMN by type of first cancer and time since the first
cancer
First cancer type 3–9 years after 10–19 years 20–29 years 30 years or more
first cancer after first cancer after first cancer after first cancer
RRa (O) EARa RR (O) EAR RR (O) EAR RR (O) EAR
Ewing’s sarcoma 55 (6) 75 20 (3) 59 20 (2) 142 0 –
Bone sarcoma 0 8 (1) 20 0 – 0 –
Soft tissue sarcoma 27 (10) 27 15 (8) 29 8 (4) 42 0 –
Neuroblastoma 3 (1) 2 9 (3) 10 15 (5) 57 10 (1) 99
Wilm’s tumour 5 (2) 3 9 (6) 12 4 (3) 15 0 –
Central nervous system 16 (7) 15 7 (6) 15 2 (2) 4 0 –
Bilateral retinoblastoma 75 (3) 61 140 (3) 15 0 – 100 (1) 955
Unilateral retinoblastoma 0 – 0 – 0 – 0 –
Hodgkin’s disease 18 (6) 24 10 (5) 31 9 (2) 56 0 –
Non-Hodgkin’s lymphoma 15 (5) 17 14 (5) 33 11 (2) 63 0 –
Others 15 (5) 17 10 (5) 24 0 – 2 (1) 36
Total 16 (45) 16 11 (45) 21 6 (20) 27 2 (3) 16
a First 3 years of follow-up were not taken in account. O: observed number of SMN.
Table 6 Relative risk (RR) and excess absolute risk (EAR) per 10–4 person-years of solid SMN by type of first cancer and attained age
First cancer type 3–9 years of age 10–19 years of age 20–29 years or age 30 years or more of age
RRa (Oa) EAR RR (O) EAR RR (O) EAR RR (O) EAR
Ewing’s sarcoma 0 63 (5) 71 25 (4) 79 17 (2) 150
Bone sarcoma 0 0 – 5 (1) 16 0
Soft tissue sarcoma 0 7 41 (15) 43 7 (4) 19 3 (2) 23
Neuroblastoma 4 (1) 3 7 (2) 5 15 (5) 44 9 (2) 91
Wilm’s tumour 0 9 (5) 8 7 (5) 18 2 (1) 9
Central nervous system 14 (1) 18 7 (8) 17 3 (3) 7 1 (2) 5
Bilateral retinoblastoma 50 (2) 70 150 (3) 119 0 0 100 (1) 867
Unilateral retinoblastoma 0 0 0 0 0
Hodgkin’s disease 0 17 (4) 19 10 (5) 30 12 (4) 88
Non-Hodgkin’s lymphoma 25 (1) 21 17 (5) 19 11 (4) 31 7 (2) 63
Others 0 28 (7) 29 6 (3) 16 1 (1) 6
Total 7 (6) 7 20 (54) 21 8 (34) 22 4 (17) 31
aFirst 3 years of follow-up were not taken in account. O: Observed number of SMN.Second cancers after a first cancer in childhood 1889
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pattern of the variations of the RR but, due to the small number of
patients of each first cancer type, the power of the test was low.
The decrease observed in the RR of solid SMN (Table 5) with time
following Hodgkin’s disease (P = 0.2) and neuroblastoma
(P = 0.1), and in EAR of solid SMN with time following central
nervous system tumours (P = 0.2) were not significant, but the
number of cases is small. We were not able to find any evidence
for an interaction between the type of first cancer treatment (Ct vs
Rt vs Ct + Rt) on the pattern of the variations of the RR (P = 0.8)
or of the EAR of SMN (P = 0.3).
When considering the attained age of the patients, rather than
the time since first cancer (Table 6), results were similar: the RR of
solid SMN decreased significantly with attained age (P < 0.001)
and the EAR showed an increase that was just significant
(P = 0.04). A significant interaction was found between the type of
first cancer treatment and the pattern of the variation of the EAR
(P = 0.01): the increase of the EAR with attained age was stronger
among patients treated with Ct + Rt than among those treated by
Rt alone.
The most frequent types of solid SMN were bone and soft tissue
sarcomas, thyroid, breast and brain cancers (Tables 7 and 8). Bone
and soft tissue sarcomas occurred mainly after the combination of
Rt + Ct, whereas thyroid, brain and breast cancer occurred both
after Rt, Ct or both.
Bone and soft tissue sarcoma RR and EAR significantly
increased with radiotherapy (yes/no) (P < 0.001) and the dose of
electrophil agents (P < 0.001). Of the 34 cases of bone sarcoma,
only one occurred 20 years or more after the first cancer. Thyroid
carcinoma RR and EAR significantly increased with radiation
dose to the thyroid (P < 0.001), but not with chemotherapy
(P = 0.6), and decreased with age at irradiation (P = 0.001). Breast
cancer RR and EAR significantly increased with the radiation
dose (P = 0.05) to the breasts and with the administration of
chemotherapy (P < 0.0001). Of the 13 breast cancers, 12 occurred
Table 7 Observed (O) and expected (E) number of SMN by type of first cancer
Solid SMN
First cancer Bone Soft-tissue Brain Thyroid Breast Melanoma Others
O (E) O (E) O (E) O (E) O (E) O (E) O (E)
Ewing’s sarcoma 8 (0.014) 3 (0.009) 0 (0.010) 0 (0.007) 0 (0.032) 0 (0.034) 0 (0.265)
Bone sarcoma 0 (0.014) 0 (0.010) 0 (0.015) 1 (0.008) 0 (0.045) 0 (0.042) 0 (0.327)
Soft tissue sarcoma 11 (0.064) 4 (0.041) 2 (0.055) 2 (0.032) 2 (0.153) 0 (0.145) 2 (1.141)
Neuroblastoma 1 (0.053) 1 (0.032) 1 (0.046) 5 (0.020) 2 (0.082) 0 (0.077) 0 (0.766)
Wilm’s tumour 1 (0.096) 2 (0.058) 1 (0.072) 2 (0.042) 1 (0.140) 2 (0.170) 2 (1.485)
Central nervous system 2 (0.083) 2 (0.058) 5 (0.084) 1 (0.052) 1 (0.394) 3 (0.265) 1 (1.858)
Bilateral retinoblastoma 5 (0.005) 1 (0.003) 0 (0.006) 0 (0.001) 0 (0.001) 0 (0.004) 1 (0.067)
Unilateral retinoblastoma 0 (0.005) 0 (0.003) 0 (0.004) 0 (0.001) 0 (0.001) 0 (0.004) 0 (0.063)
Hodgkin’s disease 2 (0.040) 2 (0.028) 1 (0.033) 2 (0.021) 4 (0.061) 0 (0.103) 2 (0.797)
Non-Hodgkin’s lymphoma 3 (0.044) 1 (0.028) 2 (0.031) 1 (0.018) 1 (0.077) 0 (0.080) 5 (0.719)
Others 1 (0.047) 2 (0.033) 0 (0.052) 0 (0.032) 2 (0.291) 1 (0.158) 6 (1.096)
Total 34 (0.466) 18 (0.303) 12 (0.409) 14 (0.234) 13 (1.277) 6 (1.081) 19 (8.583)
Table 8 Number of patients, type of treatment, observed number of SMN, mean age at SMN, excess absolute risk and relative risk of SMN, by type of SMN
Site of the SMN Patients First cancer treatment (n) Mean age at EARa/105 PY RRa
SMN in years (95% Cl) (95% Cl)
No Rt no Ct Rt no Ct Ct no Rt Rt & Ct (range)
(%) (%) (%) (%)
Bone sarcoma 34 0 4 (12%) 2 (6%) 28 (82%) 15 (6–34) 64 (44–87) 73 (51–100)
Soft tissue sarcoma 18 0 3 (17%) 1 (6%) 14 (78%) 22 (11–34) 33 (20–52) 59 (36–91)
Thyroid 14 0 7 (50%) 0 7 (50%) 22 (14–28) 26 (14–42) 60 (34–97)
Breast 13 1 4 (31%) 2 (15%) 6 (46%) 28 (12–38) 41 (18–74) 11 (6–18)
Brain 12 0 8 (67%) 1 (8%) 3 (25%) 17 (8–30) 22 (12–38) 29 (16–49)
Malignant melanoma 6 0 2 (33%) 1 (17%) 3 (50%) 23 (16–30) 7 (0–19) 6 (2–11)
Others 16 2 (12%) 3 (19%) 1 (6%) 10 (63%) 23 (4–38) 10 (0–26) 2 (1–3)
aFirst 3 years of follow-up were not taken in account. Rt, radiotherapy; Ct, chemotherapy.1890 F de Vathaire et al
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in women who had attained the age of 20 years or more. After
Hodgkin’s disease, the breast cancer RR was 76 (95% CI,24–177).
Brain cancer RR increased significantly with average radiation
dose to the brain (P = 0.05) and non-significantly with antimetabo-
lites (P = 0.1), and significantly decreased with age at first cancer
(P = 0.05). Among the 11 brain cancers, five appeared 10 years or
more after the first cancer.
Neither radiotherapy nor chemotherapy
Three solid SMN occurred among the 406 patients treated by
surgery alone, compared to 2.0 expected SMN (RR = 1.5, 95% CI,
0.6–4) (Tables 9 and 10). Two of these occurred among women: a
breast cancer at the age of 12 years, 9 years after a rhabdomyosar-
coma, and a malignant histocytosis at the age of 16 years, 9 years
after a malignant melanoma. The other occurred in a man: a
colorectal cancer at the age of 29 years, 26 years after a rhabdo-
myosarcoma.
Radiotherapy without chemotherapy
Thirty-one patients developed a solid SMN among the 1045
treated with radiotherapy alone, compared to 5.6 expected
(RR = 5.6, 95% CI = 3.8–7.8) (Table 9). The cumulative incidence
of solid SMN was 3.9% (95% CI = 2.3–5.5), 25 years after radio-
therapy for the first cancer (Figure 1). The sites of solid SMN were
the brain (eight cases observed, 0.18 expected), thyroid (seven
cases, 0.098 expected), breast (four cases, 0.79 expected), bone
(four cases, 0.15 expected), soft tissue (three cases, 0.11 expected),
skin melanoma (two cases, 0.52 expected), and lung cancer,
bladder cancer and non-Hodgkin’s lymphoma (one case each).
Table 9 Solid SMN according to time since first cancer and to type of first cancer treatment
Treatment and years Patients at risk at Solid SMN Annual incidence/104 PY Relative risk
after first cancer start of period (95% Cl)
Observed Expected Total (95% Cl) Excess (95% Cl)
No Rt no Ct 406 3 2.0 5 (1–12) 3 (<0–10) 2 (0.5–4.0)
3–9 406 2 0.25 8 (1–25) 7 (0.5–23) 8 (1–25)
10–19 308 0 0.54 0a –0.5a 0 (0–4)
20–29 174 1 0.80 8 (0.5–36) 2 (<0–32) 1 (0.1–6)
³30 63 0 0.37 0 (<0–77) –6 (<0–73) 0 (0–5)
Rt no Ct 1045 31 5.6 18 (12–25) 15 (9–22) 6 (4–8)
3–9 1045 8 0.71 12 (6–22) 11 (4–21) 11 (5–21)
10–19 831 11 1.59 17 (9–29) 15 (6–26) 7 (4–12)
20–29 456 9 1.96 29 (14–52) 23 (9–47) 5 (2–8)
³30 177 3 1.31 35 (9–89) 20 (<0–80) 2 (0.6–6)
Ct no Rt 885 8 1.1 11 (5–21) 10 (3–19) 8 (3–14)
3–9 885 4 0.54 8 (2–18) 7 (1–17) 7 (2–17)
10–19 380 3 0.33 16 (4–43) 15 (2–41) 9 (2–24)
20–29 66 1 0.15 33 (2–146) 28 (<0–140) 7 (0.4–29)
³30 7 0 0.04 0 (<0–733) –6a 0 (0–27)
Rt and Ct 2064 71 3.8 32 (25–40) 30 (23–39) 19 (15–24)
3–9 2064 31 1.32 25 (17–35) 24 (16–34) 23 (16–33)
10–19 1378 31 1.71 38 (26–53) 36 (24–50) 19 (12–25)
20–29 366 9 0.70 62 (30–111) 54 (23–104) 13 (6–23)
³30 23 0 0.05 0 (<0–417) –5 (<0–418) 0a
+ First 3 years of follow-up were not taken in account. Rt, radiotherapy; Ct, chemotherapy. aNo convergence was obtained.
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The mean annual incidence of solid SMN significantly
increased from 120 (95% CI, 80–294) cases per 105 PY 3–9 years
after the first cancer to 345 cases per 105 PY (95% CI, 86–894) 30
years or more later (P < 0.0001). The EAR reached a plateau 20
years after the first cancer, and the RR decreased from 11 (95% CI,
5–21) 3–9 years after the first cancer to 2.3 (95% CI, 0.6–5.9) 30
years or more after (Table 9) (P < 0.0001). A similar pattern was
observed according to attained age (Table 10). These results have
been detailed elsewhere (de Vathaire et al, 1995).
Chemotherapy without radiotherapy
A total of eight patients developed a SMN after chemotherapy
alone compared to 1.1 SMN expected (RR = 7.6, 95%
CI = 3.5–14): two bone sarcomas (0.06 expected, RR = 32, 95%
CI = 5.4–99), two breast cancers (0.05 expected, RR = 44, 95%
CI = 7.3–135), brain cancer, soft tissue sarcoma, Hodgkin’s
disease and malignant histiocytosis (one case of each). The cumu-
lative incidence of SMN 25 years after the first cancer was
2.7% (95% CI = 0.3–5.4). A temporal analysis was not possible
because of the very short mean follow-up of 11 years (Tables 9
and 10).
Both radiotherapy and chemotherapy
A total of 71 patients developed a solid SMN, compared to 3.8
expected (RR = 19, 95% CI = 15–24). The sites were the bone (28
cases observed, 0.20 expected, RR = 139, 95% CI = 94–197), soft
tissue (14 cases, 0.12 expected, RR = 115, 95% CI = 65–185),
thyroid (seven cases, 0.08 expected, RR = 86, 95% CI = 37–166),
breast (six cases, 0.15 expected, RR = 40, 95% CI = 16–81), brain
(three cases, 0.12 expected, RR = 26, 95% CI = 5.5–67), liver
(three cases, 0.13 expected, RR = 9.3, 95% CI = 2.2–24)
melanoma (three cases, 0.12 expected, RR = 9.9, 95%
CI = 2.5–26), kidney (two cases, 0.15 expected, RR = 13, 95%
CI = 0–33), and stomach, pancreas, multiple myeloma and
parathyroid gland (one case each). The primary sites of a sarcoma
and of a carcinoma were not localized. The 25-year cumulative
incidence of solid SMN was 7.7% (95% CI = 5.4–9.9).
The RR of solid SMN significantly decreased with time since
first cancer (P < 0.05) (Table 9) and with attained age (P < 0.05)
(Table 10). This decrease remained significant (P < 0.05), when
adjusted for age at first cancer, sex, country of treatment, first
cancer type and the total number of moles of electrophil agents,
and (P < 0.05) when patients known to be predisposed to SMN
(five Recklinghausen, 14 Li–Fraumeni) were excluded. The same
result remained significant (P < 0.05) when the analysis was
restricted to the 1885 patients treated with external radiotherapy,
for which the dose had been estimated, and when adjusted for the
average dose of radiation received by the thyroid, brain, breast and
digestive tract.
In contrast, the EAR of solid SMN significantly increased with
time after irradiation (P < 0.05) and attained age (P < 0.005) from
Table 10 Solid SMN according to attained age and first cancer treatment
Treatment and attained Patients at risk at Solid SMN Annual incidence/104 PY Relative risk
age start of period (95% Cl)
Observed Expected Total (95% Cl) Excess (95% Cl)
No Rt no Ct 406 3 2.0 5 (1–12) 3 (<0–10) 2 (0.5–4.0)
3–9 406 0 0.09 0 (0–17) –0.5a 0 (0–22)
10–19 353 2 0.26 8 (1–25) 7 (0.5–24) 8 (1–24)
20–29 252 1 0.56 5 (0.3–23) 2 (<0–20) 2 (0.1–7)
³30 124 0 1.01 0 (0–20) –4a 0 (0–2)
Rt no Ct 1045 31 5.6 18 (12–25) 15 (9–22) 6(4–8)
3–9 1045 3 0.15 14 (3–36) 13 (3–35) 19 (5–50)
10–19 988 9 0.70 14 (6–24) 12 (5–23) 13 (6–23)
20–29 730 10 1.79 18 (9–32) 15 (6–29) 6 (3–10)
³30 377 9 2.92 33 (16–60) 25 (8–52) 3 (1–6)
Ct no Rt 885 8 1.1 11 (5–21) 10 (3–19) 8 (3–14)
3–9 885 1 0.23 4 (0.2–17) 3 (<0–16) 4 (0.3–19)
10–19 735 4 0.40 11 (4–26) 10 (2–25) 10 (2–23)
20–29 228 2 0.29 22(4–66) 18 (1–64) 7 (1–24)
³30 30 1 0.14 66 (4–289) 60 (<0–283) 7 (0.4–31)
Rt and Ct 2064 71 3.8 32 (25–40) 30 (23–39) 19 (15–24)
3–9 2064 4 0.35 9 (3–20) 8 (2–19) 11 (4–26)
10–19 1906 39 1.32 33 (24–45) 32 (23–43) 29 (21–40)
20–29 1000 21 1.66 41 (26–61) 38 (23–58) 13 (8–19)
³30 166 7 0.43 128 (55–248) 120 (46–239) 16 (7–31)
+ First 3 years of follow-up were not taken in account. Rt, radiotherapy; Ct; chemotherapy.a No convergence was obtained.240 (95% CI; 159–337) cases per 105 PY between 3 and 9 years
after the first treatment to 548 cases per 105 PY (95% CI,
226–1039) 20 years or more after, this increase remaining signifi-
cant after adjustment for treatment and first cancer type (P < 0.01
in all cases).
DISCUSSION
This study of the incidence of solid second malignant neoplasms
in a cohort of 4400 patients treated for a first cancer in childhood,
and followed up for 15 years on average, revealed a significant
increase in the annual excess incidence of a solid SMN (P = 0.01),
and a decrease in the relative risk, with time since treatment of the
first cancer, both for patients treated with radiotherapy alone
(P < 0.0001) and for those treated with radiotherapy plus
chemotherapy (P < 0.05), during a period of at least 30 years after
the first cancer.
The reference cancer incidence registry we used did not cover
the study area. This choice could have biased the estimation of the
decrease in the RR if the Danish general population below 40
years of age had recently experienced a strong increase in cancer
incidence, and if such an increase had not occurred in France and
the UK. However, statistics published on cancer incidence do not
show any sign of such a phenomenon (Parkin et al, 1993).
Among our cohort, 532 (12.1%) patients were lost to follow-up.
These patients were not different from the others by sex (45%
women) or diagnostic date (1975 on average). They were more
frequently bilateral retinoblastoma (4% vs 2%) (P = 0.09). They
received a lower number of moles of drug (22 vs 36 moles m–2)
(P < 0.01), a similar average radiation dose to thyroid (4.6 vs 4.4
Gy), to breast (3.2 vs 3.4 Gy), to stomach (5.4 vs 5.6 Gy) and to
brain (7.6 vs 8.0 Gy).
The finding that the solid SMN RR decreased with time since
first cancer and attained age, both after radiotherapy alone and
after radiotherapy plus chemotherapy, is consistent with results
concerning the overall risk of solid cancer after irradiation during
childhood for other reasons (UNSCEAR, 1994; Little et al, 1997).
This study also leads us to conclude that chemotherapy signifi-
cantly increases the risk of solid cancer in patients treated with
radiotherapy, but does not significantly affect the temporal pattern
of the risk after the first cancer. Although other studies of SMN
occurrence after first cancer were not able to control for the varia-
tion in the radiation dose distribution and in aggressiveness of the
chemotherapy according to the period of treatment, our results
may be compared with those of the other major studies. Our result
concerning a significant decrease in solid SMN RR with time
since treatment is in agreement with the finding of a study based
on data from registries: a cohort of 30 880 patients treated in child-
hood or adolescence (Olsen et al, 1993). Two other cohort studies,
comprising 10 106 3-year survivors followed 6 years in average
(Tucker et al, 1984) and 9170 2-year survivors followed 8 years in
average (Hawkins et al, 1987), found no evidence of a variation in
the RR of SMN with time since the first cancer.
Excess absolute risk, which is of major clinical interest, was
found to significantly increase with time since first cancer, at least
during the initial 30 years after first cancer, and also with attained
age. In our cohort, this increase was mainly due to breast and brain
cancer. This result is in agreement with those of all the other
cohort studies of SMN after first cancer in childhood (Tucker et al,
1984; Hawkins et al, 1987; Olsen et al, 1993). It was not due to a
variation in the distribution of the radiation dose or in the aggres-
siveness of the chemotherapy according to the year of treatment.
Indeed, it remained after controlling for these factors.
We found a relative risk of breast cancer after Hodgkin’s disease
of 76 (95% CI; 24–177), which is similar to the 75 (95% CI;
45–118) reported by Bhatia et al (1996) among 483 women treated
for Hodgkin’s disease during childhood. Although compatible, the
cumulative risk of breast cancer at 40 years of age in our cohort
was significantly lower than in this cohort (19% vs 35%). We
found that the risk of thyroid cancer significantly increased with
the dose of radiation, but not with chemotherapy, which is in
agreement with the findings of Tucker et al (1991). The very high
proportion (8/31) of second brain cancers among second cancers
occurring in patients treated with radiotherapy alone was due to
the high proportion of cancers of the central nervous system as the
first cancer among patients treated with radiotherapy alone in our
cohort (423/1046), particularly due to recruitment in British
centres. These patients had received much higher doses to the
brain and hence developed more second brain cancers of a
different histological type. This higher risk totally disappeared
after adjustment for the dose to the brain.
It has to be noted that patients in our cohort were young at the
end of the follow-up: 21 years on average. Hence our study deals
effectively only with solid SMN occurring during childhood or in
young adults, and is not informative about solid SMN which will
occur at later ages.
In conclusion, our study confirms that there is a high risk of
second cancer occurring after radiotherapy and/or chemotherapy
for a first cancer in childhood. On comparison with the general
population, the relative risk decreased with time since the first
cancer, but not the excess absolute risk, which increased during the
period of at least 30 years after the first cancer. As compared to
radiotherapy alone, the addition of chemotherapy increases the
risk of SMN after a first cancer in childhood, but does not modify
the variation of this risk during the time after the first cancer.
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